Malignant Neoplasm of Stomach Terminated Phase 2 Trials for Capecitabine (DB01101)

Also known as: Gastric Cancers / Stomach Cancer / Gastric cancer / Gastric Malignancies / Gastric cancer NOS / Cancer of Stomach / Malignant neoplasm of stomach, unspecified / Gastric malignancy

IndicationStatusPhase
DBCOND0045917 (Malignant Neoplasm of Stomach)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02216149Effects of S-1 and Capecitabine on Coronary Artery Blood FlowTreatment
NCT01702558A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)Treatment
NCT02485834FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction CancerTreatment
NCT00354224Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Stomach CancerTreatment
NCT00335959S0425 Oxaliplatin, Capecitabine, and RT in Treating Patients W/Stomach Cancer That Can Be Removed By SurgeryTreatment
NCT00848783Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) CancersTreatment
NCT01123473Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction CancerTreatment